help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santen, R. J.
Right arrow Articles by Wells, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santen, R. J.
Right arrow Articles by Wells, S. A.

Journal of Clinical Endocrinology & Metabolism, Vol 51, 473-477, Copyright © 1980 by Endocrine Society

ARTICLES

Resistance of the ovary to blockade of aromatization with aminoglutethimide

RJ Santen, E Samojlik and SA Wells

Aminoglutethimide (AG) is a potent inhibitor of aromatization in placental microsomes and in peripheral tissues in postmenopausal women. Aromatase inhibitors have been used to block estrogen production and induce breast tumor regression in rodents. To inhibit ovarian estrogen production, we administered various doses of AG and its highly potent D- stereoisomer to premenopausal women with breast carcinoma. However, at no dose level did AG consistently lower estrone and estradiol concentrations in plasma below those observed in normal menstruating women. Uniform increments in LH and FSH were also not observed. Only during the luteal phase were the levels of estradiol (but not estrone) significantly suppressed. These observations are best explained by the possibility that aromatase enzymes in the ovary, as opposed to those in the placenta and in peripheral tissues, are partially resistant to the effects of AG.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. J. Santen
To Block Estrogen's Synthesis or Action: That Is the Question
J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3007 - 3012.
[Full Text] [PDF]

Home page
 JCOHome page
P. E. Goss and K. Strasser
Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer
J. Clin. Oncol., February 1, 2001; 19(3): 881 - 894.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
C. R. Jefcoate, J. G. Liehr, R. J. Santen, T. R. Sutter, J. D. Yager, W. Yue, S. J. Santner, R. Tekmal, L. Demers, R. Pauley, et al.
Chapter 5: Tissue-Specific Synthesis and Oxidative Metabolism of Estrogens
J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 95 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
V. N. Kristensen, E. K. Haraldsen, K. B. Anderson, P. E. Lonning, B. Erikstein, R. Karesen, O. S. Gabrielsen, and A.-L. Borresen-Dale
CYP17 and Breast Cancer Risk: The Polymorphism in the 5' Flanking Area of the Gene Does Not Influence Binding to Sp-1
Cancer Res., June 1, 1999; 59(12): 2825 - 2828.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1980 by The Endocrine Society